Alphatec Holdings, Inc.（ATEC）資訊與事件ATECAlphatec Holdings, Inc.

Company Reaffirms FY2026 Revenue Outlook, Raises EBITDA Guidance to $140 Million

The Company is reaffirming its full-year revenue outlook and increasing adjusted EBITDA guidance following a second quarter characterized by strong case volume growth, continued surgeon adoption, expanding profitability, and positive free cash flow generation. For fiscal year 2026, the Company continues to expect total revenue of approximately $882 million, including approximately $805 million of surgical revenue and approximately $77 million of EOS revenue. This outlook represents approximately 15% total revenue growth and approximately 17% surgical revenue growth for the year. The Company now expects adjusted EBITDA of approximately $140 million, an increase from its prior expectation of approximately $134 million, reflecting continued progress in operating leverage and margin expansion. The Company also continues to expect at least $20 million of free cash flow for fiscal year 2026.

ATEC Reports Q2 Revenue of $214M, Exceeds Expectations

Reports Q2 reeveenue $214M, consensus $211.27M. "ATEC's procedural approach continues to create true distinction in the spine market," said Pat Miles, Chairman and Chief Executive Officer. "During the quarter, we saw 20 percent case volume growth, continued to expand our surgeon user base, and generated strong profitability. Surgeons understand that better technology, workflows, and data can transform the surgical experience and drive improved patient outcomes. With ATEC's dedication to clinical innovation, data-driven decision-making, and sales execution, our opportunity to earn surgeon trust remains substantial, allowing us to create long-term value for years to come."

ATEC Reports Q1 Revenue of $192.1M, Below Expectations

Reports Q1 revenue $192.1M, consensus $196.6M. "ATEC's surgical business continues to demonstrate strong momentum, with volume-driven growth and increasing surgeon adoption reinforcing the strength of our procedural approach," said Pat Miles, Chairman and Chief Executive Officer. "We are adjusting our EOS expectations, but the underlying fundamentals of our business are strong and our conviction in the long-term opportunity has not changed. We are confident that our data-driven procedural ecosystem improves patient outcomes, which in turn drives durable growth, expanding margins, and long-term value."